의약품 수탁제조 시장 규모, 점유율, 동향 분석 : 제품별, 의약품별, 서비스별, 사업 규모별, 워크플로우별, 용도별, 최종 용도별, 기업 규모별, 지역별, 부문별 예측(2025-2030년)

Pharmaceutical Contract Manufacturing Market Growth & Trends:

The global pharmaceutical contract manufacturing market size is expected to reach USD 224.51 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 9.84% from 2025 to 2030. Growth in the market can be attributed to benefits offered to pharmaceutical companies, such as cost efficiencies, the ability to leverage contract manufacturing facilities to streamline production, and the opportunity to focus on core competencies. In addition, the market is driven by the increasing demand for biologics, biosimilars, high-potency active pharmaceutical ingredients (HPAPIs), and personalized medicine.

The expansion of pharmaceutical companies into new product innovations has led to the increased demand for contract manufacturing organization (CMO) services for clinical trials, packaging, and regulatory compliance. Technological integrations among CMOs, such as continuous manufacturing, automation, and AI-driven process optimization, are further propelling pharmaceutical production. These innovations enhance efficiency, reduce waste, and improve product quality and standards.

The pharmaceutical contract manufacturing industry is expected to experience continued growth during the forecast period, as CMO providers play a crucial role in helping companies meet the regulatory requirements of the FDA, EMA, and ICH. Moreover, the growing demand for both branded and generic drugs is a significant factor in the expansion of the pharmaceutical contract manufacturing industry. As various generic drugs reach patent expiration, pharmaceutical companies are innovating new generic versions to meet this demand. Hence, many of these pharmaceutical companies are relying on CMO services to fulfill market needs efficiently and effectively.

In addition, regulation is one of the significant factors for pharmaceutical products that have fueled the demand for pharmaceutical contract manufacturing. The FDA plays a pivotal role in ensuring the safety and efficiency of pharmaceuticals in the market. Likewise, strategic partnerships and accelerating product launches drive market growth. For instance, in December 2024, Lonza mentioned the expansion of its service offering orally delivered biologic therapies to support innovative capsule companies' unique development and manufacturing needs. The product launch will help patients explore innovative delivery solutions to mitigate bioavailability challenges.

Pharmaceutical Contract Manufacturing Market Report Highlights:

• The API manufacturing segment dominated the market with a share of 70.68% in 2024. Growth in the segment can be attributed to increasing HPAPI production, rising demand for continuous API manufacturing, growing FDA approval for the market, and the launch of new products.
• Based on product, the small molecule segment held the largest market share in 2024, which is attributed to the increasing demand for generics, specialty drugs, and HPAPIs, and growing innovations of drugs have enhanced the requirement for CMO's efficiency, scalability, and regulatory compliance further driving the market growth.
• The generics segment dominated the market in 2024 owing to the increasing prevalence of chronic diseases, growing patent expirations, and rising demand for cost-efficient drugs.
• Based on scale of operation, the batch segment dominated the market. It accounted for 88.88% in 2024, attributing to various benefits such as batch production and major support for saving operational costs.
• The commercial segment dominated the market in 2024. Growth in this segment can be attributed to the increasing launch of various products that help treat diseases.
• The oncology segment held the largest market share in 2024 based on application. This segment is driven by increasing cancer incidences and new pharmaceutical drug requirements.
• The pharmaceutical companies segment held the largest market share in 2024 based on end-use. Pharmaceutical companies utilize contract manufacturing to lower costs, increase scalability, and speed up time-to-market. CMOs offer expertise in API synthesis, formulation, and regulatory compliance. In addition, outsourcing provides access to advanced technologies, flexible production capacity, and optimized global supply chains.
• The small company size segment dominated the market in 2024 due to increasing employee strengths, facilities, and venture funding.
• Asia Pacific is expected to register the fastest growth rate of 10.80% CAGR over the forecast period. Due to the rising number of pharmaceutical companies & contract manufacturing organizations in countries like Japan, China, and India, Asia Pacific will likely witness rapid growth over the estimated time. Furthermore, the availability of a skilled workforce within the region at a lower cost compared to the U.S. is another factor that is anticipated to propel the market growth.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Product
  • 1.2.3. Drug
  • 1.2.4. Scale of Operation
  • 1.2.5. Workflow
  • 1.2.6. Application
  • 1.2.7. End Use
  • 1.2.8. Company Size
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technological Advancements
• 3.4. Clinical trials volume analysis (2024)
• 3.5. Pharmaceutical Contract Manufacturing Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Analysis
  • 3.5.2. PESTEL Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical Contract Manufacturing Market: Service Estimates & Trend Analysis

• 4.1. Pharmaceutical Contract Manufacturing Market, By Service: Segment Dashboard
• 4.2. Pharmaceutical Contract Manufacturing Market, By Service: Movement Analysis
• 4.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Service, 2018 - 2030
• 4.4. API Manufacturing
  • 4.4.1. API Manufacturing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Finished Drug Product Manufacturing
  • 4.5.1. Finished Drug Product Manufacturing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Oral Solids
    • 4.5.2.1. Oral Solids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Liquids
    • 4.5.3.1. Liquids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Topical
    • 4.5.4.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Packaging Services
  • 4.6.1. Packaging Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Contract Manufacturing Market: Product Estimates & Trend Analysis

• 5.1. Pharmaceutical Contract Manufacturing Market, By Product: Segment Dashboard
• 5.2. Pharmaceutical Contract Manufacturing Market, By Product: Movement Analysis
• 5.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Product, 2018 - 2030
• 5.4. Small Molecule
  • 5.4.1. Small Molecule Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Biologics
  • 5.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Monoclonal Antibodies
    • 5.5.2.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Vaccines
    • 5.5.3.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. Recombinant Proteins
    • 5.5.4.1. Recombinant Proteins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pharmaceutical Contract Manufacturing Market: Drug Estimates & Trend Analysis

• 6.1. Pharmaceutical Contract Manufacturing Market, By Drug: Segment Dashboard
• 6.2. Pharmaceutical Contract Manufacturing Market, By Drug: Movement Analysis
• 6.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Drug, 2018 - 2030
• 6.4. Generics
  • 6.4.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Branded
  • 6.5.1. Branded Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmaceutical Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis

• 7.1. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Segment Dashboard
• 7.2. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Movement Analysis
• 7.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Scale of Operation, 2018 - 2030
• 7.4. Batch
  • 7.4.1. Batch Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Continuous
  • 7.5.1. Continuous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Pharmaceutical Contract Manufacturing Market: Workflow Estimates & Trend Analysis

• 8.1. Pharmaceutical Contract Manufacturing Market, By Workflow: Segment Dashboard
• 8.2. Pharmaceutical Contract Manufacturing Market, By Workflow: Movement Analysis
• 8.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Workflow, 2018 - 2030
• 8.4. Clinical
  • 8.4.1. Clinical Market, 2018 to 2030, (USD Million)
• 8.5. Commercial
  • 8.5.1. Commercial Market, 2018 to 2030, (USD Million)

Chapter 9. Pharmaceutical Contract Manufacturing Market: Application Estimates & Trend Analysis

• 9.1. Pharmaceutical Contract Manufacturing Market, By Application: Segment Dashboard
• 9.2. Pharmaceutical Contract Manufacturing Market, By Application: Movement Analysis
• 9.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Application, 2018 - 2030
• 9.4. Oncology
  • 9.4.1. Oncology Market, 2018 to 2030, (USD Million)
• 9.5. Infectious Diseases
  • 9.5.1. Infectious Diseases Market, 2018 to 2030, (USD Million)
• 9.6. Neurological Disorders
  • 9.6.1. Neurological Disorders Market, 2018 to 2030, (USD Million)
• 9.7. Cardiovascular Disease
  • 9.7.1. Cardiovascular Disease Market, 2018 to 2030, (USD Million)
• 9.8. Metabolic Disorders
  • 9.8.1. Metabolic Disorders Market, 2018 to 2030, (USD Million)
• 9.9. Autoimmune Diseases
  • 9.9.1. Autoimmune Diseases Market, 2018 to 2030, (USD Million)
• 9.10. Respiratory Diseases
  • 9.10.1. Respiratory Diseases Market, 2018 to 2030, (USD Million)
• 9.11. Ophthalmology
  • 9.11.1. Ophthalmology Market, 2018 to 2030, (USD Million)
• 9.12. Gastrointestinal Disorders
  • 9.12.1. Gastrointestinal Disorders Market, 2018 to 2030, (USD Million)
• 9.13. Hormonal Disorders
  • 9.13.1. Hormonal Disorders Market, 2018 to 2030, (USD Million)
• 9.14. Hematological Disorders
  • 9.14.1. Hematological Disorders Market, 2018 to 2030, (USD Million)
• 9.15. Others
  • 9.15.1. Others Market, 2018 to 2030, (USD Million)

Chapter 10. Pharmaceutical Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 10.1. Pharmaceutical Contract Manufacturing Market, By End Use: Segment Dashboard
• 10.2. Pharmaceutical Contract Manufacturing Market, By End Use: Movement Analysis
• 10.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 - 2030
• 10.4. Pharmaceutical Companies
  • 10.4.1. Pharmaceutical Companies Market, 2018 to 2030, (USD Million)
• 10.5. Biotechnology Companies
  • 10.5.1. Biotechnology Companies Market, 2018 to 2030, (USD Million)

Chapter 11. Pharmaceutical Contract Manufacturing Market: Company Size Estimates & Trend Analysis

• 11.1. Pharmaceutical Contract Manufacturing Market, By Company Size: Segment Dashboard
• 11.2. Pharmaceutical Contract Manufacturing Market, By Company Size: Movement Analysis
• 11.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Company Size, 2018 - 2030
• 11.4. Small
  • 11.4.1. Small Market, 2018 to 2030, (USD Million)
• 11.5. Medium
  • 11.5.1. Medium Market, 2018 to 2030, (USD Million)
• 11.6. Large
  • 11.6.1. Large Market, 2018 to 2030, (USD Million)

Chapter 12. Pharmaceutical Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 12.1. Regional Market Share Analysis, 2024 & 2030
• 12.2. Regional Market Dashboard
• 12.3. Global Regional Market Snapshot
• 12.4. North America
  • 12.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.4.2. U.S
    • 12.4.2.1. Key Country Dynamics
    • 12.4.2.2. Competitive Scenario
    • 12.4.2.3. Regulatory Framework
    • 12.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.4.3. Canada
    • 12.4.3.1. Key Country Dynamics
    • 12.4.3.2. Competitive Scenario
    • 12.4.3.3. Regulatory Framework
    • 12.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.4.4. Mexico
    • 12.4.4.1. Key Country Dynamics
    • 12.4.4.2. Competitive Scenario
    • 12.4.4.3. Regulatory Framework
    • 12.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.5. Europe
  • 12.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.2. UK
    • 12.5.2.1. Key Country Dynamics
    • 12.5.2.2. Competitive Scenario
    • 12.5.2.3. Regulatory Framework
    • 12.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.3. Germany
    • 12.5.3.1. Key Country Dynamics
    • 12.5.3.2. Competitive Scenario
    • 12.5.3.3. Regulatory Framework
    • 12.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.4. France
    • 12.5.4.1. Key Country Dynamics
    • 12.5.4.2. Competitive Scenario
    • 12.5.4.3. Regulatory Framework
    • 12.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.5. Italy
    • 12.5.5.1. Key Country Dynamics
    • 12.5.5.2. Competitive Scenario
    • 12.5.5.3. Regulatory Framework
    • 12.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.6. Spain
    • 12.5.6.1. Key Country Dynamics
    • 12.5.6.2. Competitive Scenario
    • 12.5.6.3. Regulatory Framework
    • 12.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.7. Denmark
    • 12.5.7.1. Key Country Dynamics
    • 12.5.7.2. Competitive Scenario
    • 12.5.7.3. Regulatory Framework
    • 12.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.8. Sweden
    • 12.5.8.1. Key Country Dynamics
    • 12.5.8.2. Competitive Scenario
    • 12.5.8.3. Regulatory Framework
    • 12.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.9. Norway
    • 12.5.9.1. Key Country Dynamics
    • 12.5.9.2. Competitive Scenario
    • 12.5.9.3. Regulatory Framework
    • 12.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.6. Asia Pacific
  • 12.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.2. Japan
    • 12.6.2.1. Key Country Dynamics
    • 12.6.2.2. Competitive Scenario
    • 12.6.2.3. Regulatory Framework
    • 12.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.3. China
    • 12.6.3.1. Key Country Dynamics
    • 12.6.3.2. Competitive Scenario
    • 12.6.3.3. Regulatory Framework
    • 12.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.4. India
    • 12.6.4.1. Key Country Dynamics
    • 12.6.4.2. Competitive Scenario
    • 12.6.4.3. Regulatory Framework
    • 12.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.5. Thailand
    • 12.6.5.1. Key Country Dynamics
    • 12.6.5.2. Competitive Scenario
    • 12.6.5.3. Regulatory Framework
    • 12.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.6. South Korea
    • 12.6.6.1. Key Country Dynamics
    • 12.6.6.2. Competitive Scenario
    • 12.6.6.3. Regulatory Framework
    • 12.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.7. Australia
    • 12.6.7.1. Key Country Dynamics
    • 12.6.7.2. Competitive Scenario
    • 12.6.7.3. Regulatory Framework
    • 12.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.7. Latin America
  • 12.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.7.2. Brazil
    • 12.7.2.1. Key Country Dynamics
    • 12.7.2.2. Competitive Scenario
    • 12.7.2.3. Regulatory Framework
    • 12.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.7.3. Argentina
    • 12.7.3.1. Key Country Dynamics
    • 12.7.3.2. Competitive Scenario
    • 12.7.3.3. Regulatory Framework
    • 12.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.8. MEA
  • 12.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.2. South Africa
    • 12.8.2.1. Key Country Dynamics
    • 12.8.2.2. Competitive Scenario
    • 12.8.2.3. Regulatory Framework
    • 12.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.3. Saudi Arabia
    • 12.8.3.1. Key Country Dynamics
    • 12.8.3.2. Competitive Scenario
    • 12.8.3.3. Regulatory Framework
    • 12.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.4. UAE
    • 12.8.4.1. Key Country Dynamics
    • 12.8.4.2. Competitive Scenario
    • 12.8.4.3. Regulatory Framework
    • 12.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.5. Kuwait
    • 12.8.5.1. Key Country Dynamics
    • 12.8.5.2. Competitive Scenario
    • 12.8.5.3. Regulatory Framework
    • 12.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 13. Competitive Landscape

• 13.1. Market Participant Categorization
• 13.2. Company Market Share Analysis, 2023/24
• 13.3. Company Profiles
  • 13.3.1. AbbVie Contract Manufacturing
    • 13.3.1.1. Company Overview
    • 13.3.1.2. Financial Performance
    • 13.3.1.3. Service Benchmarking
    • 13.3.1.4. Strategic Initiatives
  • 13.3.2. Almac Group
    • 13.3.2.1. Company Overview
    • 13.3.2.2. Financial Performance
    • 13.3.2.3. Service Benchmarking
    • 13.3.2.4. Strategic Initiatives
  • 13.3.3. Boehringer Ingelheim BioXcellence
    • 13.3.3.1. Company Overview
    • 13.3.3.2. Financial Performance
    • 13.3.3.3. Service Benchmarking
    • 13.3.3.4. Strategic Initiatives
  • 13.3.4. Catalent
    • 13.3.4.1. Company Overview
    • 13.3.4.2. Financial Performance
    • 13.3.4.3. Service Benchmarking
    • 13.3.4.4. Strategic Initiatives
  • 13.3.5. Dr. Reddy's Laboratories
    • 13.3.5.1. Company Overview
    • 13.3.5.2. Financial Performance
    • 13.3.5.3. Service Benchmarking
    • 13.3.5.4. Strategic Initiatives
  • 13.3.6. Fareva
    • 13.3.6.1. Company Overview
    • 13.3.6.2. Financial Performance
    • 13.3.6.3. Service Benchmarking
    • 13.3.6.4. Strategic Initiatives
  • 13.3.7. Fujifilm Diosynth Biotechnologies
    • 13.3.7.1. Company Overview
    • 13.3.7.2. Financial Performance
    • 13.3.7.3. Service Benchmarking
    • 13.3.7.4. Strategic Initiatives
  • 13.3.8. Jubilant HollisterStier
    • 13.3.8.1. Company Overview
    • 13.3.8.2. Financial Performance
    • 13.3.8.3. Service Benchmarking
    • 13.3.8.4. Strategic Initiatives
  • 13.3.9. Lonza Group
    • 13.3.9.1. Company Overview
    • 13.3.9.2. Financial Performance
    • 13.3.9.3. Service Benchmarking
    • 13.3.9.4. Strategic Initiatives
  • 13.3.10. Patheon (Thermo Fisher Scientific)
    • 13.3.10.1. Company Overview
    • 13.3.10.2. Financial Performance
    • 13.3.10.3. Service Benchmarking
    • 13.3.10.4. Strategic Initiatives
  • 13.3.11. Pfizer CentreOne
    • 13.3.11.1. Company Overview
    • 13.3.11.2. Financial Performance
    • 13.3.11.3. Service Benchmarking
    • 13.3.11.4. Strategic Initiatives
  • 13.3.12. Prakruti Life Science
    • 13.3.12.1. Company Overview
    • 13.3.12.2. Financial Performance
    • 13.3.12.3. Service Benchmarking
    • 13.3.12.4. Strategic Initiatives
  • 13.3.13. Recipharm
    • 13.3.13.1. Company Overview
    • 13.3.13.2. Financial Performance
    • 13.3.13.3. Service Benchmarking
    • 13.3.13.4. Strategic Initiatives
  • 13.3.14. Samsung Biologics
    • 13.3.14.1. Company Overview
    • 13.3.14.2. Financial Performance
    • 13.3.14.3. Service Benchmarking
    • 13.3.14.4. Strategic Initiatives
  • 13.3.15. Siegfried Holding AG
    • 13.3.15.1. Company Overview
    • 13.3.15.2. Financial Performance
    • 13.3.15.3. Service Benchmarking
    • 13.3.15.4. Strategic Initiatives
  • 13.3.16. Vetter Pharma
    • 13.3.16.1. Company Overview
    • 13.3.16.2. Financial Performance
    • 13.3.16.3. Service Benchmarking
    • 13.3.16.4. Strategic Initiatives
  • 13.3.17. WuXi AppTec
    • 13.3.17.1. Company Overview
    • 13.3.17.2. Financial Performance
    • 13.3.17.3. Service Benchmarking
    • 13.3.17.4. Strategic Initiatives